Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan
Brief Summary: Primary Objective:

To compare the safety, in terms of percentage of patients with symptomatic documented hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU).

Secondary Objectives:

* To assess effect of lixisenatide versus SU on:
* Changes in glycemic control;
* Changes in body weight.
* To assess overall safety of lixisenatide and SU.


Options:
A: Arm Label: Low-dosage therapy; Type: EXPERIMENTAL; Interventions: Drug: Metformin and Glimepiride (Low Dosage), Drug: Metformin and Vildagliptin (Low Dosage), Drug: Metformin and Insulin Glargine U100 (Low Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage) | Arm Label: Regular-dosage therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin and Glimepiride (Regular Dosage), Drug: Metformin and Vildagliptin (Regular Dosage), Drug: Metformin and Insulin Glargine U100 (Regular Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage) | Intervention Type: DRUG; Name: Metformin and Glimepiride (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Glimepiride (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy
B: Arm Label: Intervention; Type: OTHER; Interventions: Other: FAST | Arm Label: Control; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: FAST; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Control
C: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin phosphate, Drug: Metformin | Arm Label: Sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin phosphate; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Comparator: Sulfonylurea; Assigned to Arm(s): Sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea
D: Arm Label: Lyxumia; Type: EXPERIMENTAL; Interventions: Drug: Lixisenatide (AVE0010), Drug: metformin, Drug: basal insulin | Arm Label: Sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: metformin, Drug: basal insulin | Intervention Type: DRUG; Name: Lixisenatide (AVE0010); Assigned to Arm(s): Lyxumia | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Sulfonylurea | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lyxumia, Sulfonylurea | Intervention Type: DRUG; Name: basal insulin; Assigned to Arm(s): Lyxumia, Sulfonylurea

Answer: D